Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for use of Endocrine therapy

Unanswered questions

Important unanswered questions about the use of endocrine therapy in hormone receptor-positive advanced breast cancer are outlined below; some of these may be addressed in ongoing trials:

  • the use of third generation aromatase inhibitors and fulvestrant in pre-menopausal women
  • which endocrine therapy is recommended for women who have progressed on adjuvant aromatase inhibitors
  • the relative benefits and harms of different aromatase inhibitors
  • the relative benefits and harms of fulvestrant
  • quality-of-life issues associated with endocrine therapy
  • long-term side effects associated with the use of endocrine therapy.

Published using CeCC Docbook Manager